Spondyloenchondrodysplasia with immune dysregulation: Role of sirolimus
- 16 March 2022
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (10) , e29672
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The Role of mTOR Inhibitors in Hematologic Disease: From Bench to BedsideFrontiers in Oncology, 2021
- Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based reviewRheumatology International, 2020
- Characterisation of ACP5 missense mutations encoding tartrate-resistant acid phosphatase associated with spondyloenchondrodysplasiaPLOS ONE, 2020
- Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive SurveyJournal of Clinical Immunology, 2016
- Three cases of spondyloenchondrodysplasia (SPENCD) with systemic lupus erythematosus: a case series and review of the literatureLupus, 2016
- Severe immune dysregulation with neurological impairment and minor bone changes in a child with spondyloenchondrodysplasia due to two novel mutations in the ACP5 genePediatric Rheumatology, 2015
- Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitorPediatric Transplantation, 2013
- Monogenic AutoimmunityAnnual Review of Immunology, 2012
- TRAPing a new gene for autoimmunityNature Genetics, 2011
- A syndrome of immunodeficiency, autoimmunity, and spondylometaphyseal dysplasiaAmerican Journal of Medical Genetics Part A, 2006